

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number  
WO 02/092000 A2

(51) International Patent Classification<sup>7</sup>: **A61K**

(21) International Application Number: PCT/US02/14877

(22) International Filing Date: 13 May 2002 (13.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/290,071	11 May 2001 (11.05.2001)	US
60/291,311	17 May 2001 (17.05.2001)	US
60/353,058	1 February 2002 (01.02.2002)	US
60/361,293	4 March 2002 (04.03.2002)	US

[US/US]; 11 Oliver Lane, Hopkinton, MA 01748-3108 (US). **ANISOWICZ, Anthony** [US/US]; 50 Upham Street, West Newton, MA 02465 (US). **GRAHAM, James, R.** [US/US]; 40 Peirce Street, Arlington, MA 02476 (US). **MORALES, Arturo** [US/US]; 230 Cedar Ave., Arlington, MA 02476 (US). **YAWORSKY, Paul, J.** [US/US]; 13 Hobart Lane, Rockland, MA 02370 (US). **LIU, Wei** [CN/US]; 73 Blackmer Road, Sudbury, MA 01776 (US).

(74) Agents: **REA, Teresa, Stanek et al.**; BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA 22313-1404 (US).


(71) Applicants (for all designated States except US): **GENOME THERAPEUTICS CORPORATION** [US/US]; 100 Beaver Street, Waltham, MA 02453 (US). **WYETH** [US/US]; Five Giralda Farms, Madison, NJ 07928 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALLEN, Kristina**

[Continued on next page]

(54) Title: **HBM VARIANT'S THAT MODULATE BONE MASS AND LIPID LEVELS**

\* G171E mutation involves the ringed R group (F) alteration and leads to marginally greater TCF-luciferase activation than that with HBM1 mutation G171V.

(57) Abstract: ABSTRACT The present invention relates to methods and materials used to express an HBM-like polypeptide derived from HBM, LRP5 or LRP6 in animal cells and transgenic animals. The present invention also relates to transgenic animals expressing the HBM-like polypeptides. The invention provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development and lipid modulation. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.



(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

— *without international search report and to be republished upon receipt of that report*